Sadre Momtaz A, Safarnejad F.
18F-alfatide II internal dosimetry using the ICRP 110 adult reference phantoms and the ICRP 103 tissue weighting factors.
Phys Med 2023;
107:102552. [PMID:
36857858 DOI:
10.1016/j.ejmp.2023.102552]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 02/02/2023] [Accepted: 02/18/2023] [Indexed: 03/03/2023] Open
Abstract
PURPOSE
18F-alfatide II is an arginine-glycine-aspartate (RGD) peptide-based PET tracer with promising imaging properties and pharmacokinetics. This study aims to calculate the absorbed and effective doses of 18F-alfatide II using the ICRP 110 adult reference phantoms and the ICRP 103 tissue weighting factors.
METHODS
The MIRD method was used in this study to calculate the absorbed dose of organs and tissues. The biokinetic data were taken from a previous study. These data are based on the whole-body PET imaging of mice.
RESULTS
The results show that the effective dose per unit activity administered of 18F-alfatide II is 1.33E-02 mSv/MBq. The urinary bladder wall receives the highest absorbed dose due to the administration of this radiopharmaceutical. Also, the effective dose of 18F-alfatide II is lower than that of 18F-FDG and some other RGD peptide-based tracers.
CONCLUSIONS
Dose calculation using ICRP 110 voxelized adult reference phantoms and ICRP 103 tissue weighting factors leads to more realistic and accurate results for 18F-alfatide II compared to the stylized phantoms. The calculated effective dose of 18F-alfatide II in the present study is lower than that of previously published data.
Collapse